A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma · Liver Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Seoul, South Korea

Study leads

Yeonhee Kim, Ph.D
Study Director
Etnova Therapeutics

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Multi-analyte Blood Test Clinical Trial

Liver Cirrhosis · Liver Cancer · HCC

Abroad (travel likely)Recruiting

Escondido, United States · Mission Hills, United States

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma · Liver Cancer Stage IV · Pulmonary Metastases

Abroad (travel likely)Recruiting

Guanzhou, China · Guanzhou, China

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer

Abroad (travel likely)RecruitingPHASE1

Goodyear, United States · Duarte, United States

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1

San Diego, United States